Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Shaikha AlQahtani"'
Publikováno v:
Current Oncology, Vol 31, Iss 5, Pp 2644-2649 (2024)
MEK inhibitors (MEKi) represent innovative and promising treatments for managing manifestations of neurofibromatosis type 1 (NF1). To mitigate potential ophthalmic side effects, such as MEKi-associated retinopathy (MEKAR), patients undergoing MEKi th
Externí odkaz:
https://doaj.org/article/bfc15549bd604b2da56bae5c6c41126f
Autor:
Faryal Munir, Viney Hardit, Irtiza N. Sheikh, Shaikha AlQahtani, Jiasen He, Branko Cuglievan, Chitra Hosing, Priti Tewari, Sajad Khazal
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 12, p 10095 (2023)
Hodgkin lymphoma, a hematological malignancy of lymphoid origin that typically arises from germinal-center B cells, has an excellent overall prognosis. However, the treatment of patients who relapse or develop resistant disease still poses a substant
Externí odkaz:
https://doaj.org/article/a2be4f3d92ef4b1896a6037adcd34f06
Autor:
Irtiza N. Sheikh, Shaikha Alqahtani, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Kris M. Mahadeo, Uday Popat, Elizabeth J. Shpall, Sajad Khazal
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8748 (2022)
Non-relapse mortality due to GVHD and infections represents a major source of morbidity and mortality in pediatric HSCT recipients. Post-transplant cyclophosphamide (PTCy) has emerged as an effective and safe GVHD prophylaxis strategy, with improved
Externí odkaz:
https://doaj.org/article/dc3b010cb4fb495696531abeaa23d4fa